PILOT TRIAL OF BARICITINIB FOR ALS PATIENTS AND ASYMPTOMATIC MUTANT C9ORF72 CARRIERS INCLUDING NOVEL PERIPHERAL IMMUNE CELL PROFILING AND CSF BIOMARKERS

The General Hospital Corporation

Investigators